Pharmacyclics surges on Imbruvica news


Shares of Pharmacyclics (PCYC +13%) come off halt and promptly rally double-digits.

Investors are cheering more positive data from clinical trials of Imbruvica (ibrutinib).

See: Imbruvica continues to impress as Phase 3 study stopped early

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs